SABR associated with higher three-year mortality than surgery in early-stage NSCLC
Among 12,546 patients with early-stage NSCLC, adjusted three-year mortality was 30.3% after SABR versus 21.6% after surgery.
Among 12,546 patients with early-stage NSCLC, adjusted three-year mortality was 30.3% after SABR versus 21.6% after surgery.
In 45 patients with hepatocellular carcinoma, MR-guided SBRT achieved 90% two-year local control without reported grade ≥3 acute toxicity.
In 60 selected patients, radical thoracic reirradiation produced 17% grade 3 toxicity and no grade 4–5 events over 26.5 months.
In lacrimal gland adenoid cystic carcinoma, 10-year locoregional recurrence-free survival was 90.5% with extended-margin RT versus 40.5% with narrower fields.
New GEC-ESTRO guidance establishes histology-specific single-fraction liver brachytherapy doses, organ-at-risk constraints, catheter implantation workflows, and follow-up recommendations.
Across 250 prostate SBRT fractions, adaptive planning prevented major target undercoverage, while most scheduled plans remained close to the prescription dose.
In 74 matched pairs, deep learning-assisted proton planning showed no significant differences in early disease control or toxicity compared with manual planning.
In matched patients with N3M0 esophageal cancer, median survival was 17.6 months after neoadjuvant versus 16.1 months after definitive chemoradiotherapy.
In 83 patients, AI-assisted tumor contouring did not shorten clinical review or contouring time, with a possible increase in nodal contour editing.
Five studies worth your time this week, spanning lung SBRT, prostate fractionation, feeding-tube strategies, plasmacytoma treatment and metastasis-directed therapy.
New GEC-ESTRO consensus standardizes target and organ-at-risk delineation for rectal HDR brachytherapy, enabling consistent dose reporting without prescribing new treatment margins.
Across 63 reviewed publications, RT–immunotherapy combinations showed promising pathological responses, but survival benefit attributable to the combined strategy remains unproven.
AAPM MPPG 18.a sets daily output constancy at ±3%, annual field alignment at ±2 mm, and physicist-led commissioning requirements for superficial RT.
Only 42.1% of prostate RT patients completed their first five fractions without preparation-related corrections, although individual-fraction success increased from 72.9% to 86.6%.
In 115 peripheral lung SBRT patients, five-year survival was 36% for left-sided lesions versus 70% for right-sided lesions, an exploratory association.